Untitled Document
Taking a Closer Look at the Stories Ignored by the Corporate Media
Donate | Fair Use Notice | Who We Are | Contact

NEWS
All News
9-11
Corporatism
Disaster in New Orleans
Economics
Environment
Globalization
Government / The Elite
Human Rights
International Affairs
Iraq War
London Bombing
Media
Police State / Military
Science / Health
Voting Integrity
War on Terrorism
Miscellaneous

COMMENTARY
All Commentaries
9-11
CIA
Corporatism
Economics
Government / The Elite
Imperialism
Iraq War
Media
Police State / Military
Science / Health
Voting Integrity
War on Terrorism

SEARCH/ARCHIVES
Advanced Search
View the Archives

E-mail this Link   Printer Friendly

CORPORATISM -
-

Diseases of rich deprive poor of drugs

Posted in the database on Monday, September 12th, 2005 @ 09:34:59 MST (1389 views)
by Anushka Asthana    The Observer  

Untitled Document

The world's poorest people are being denied access to drugs because pharmaceutical companies are focusing their resources on diseases suffered by wealthy, middle-aged Americans, such as obesity and heart disease, a leading expert will say tomorrow.

Dr David Rhodes, the Health Protection Agency's (HPA) head of business development, will claim that spiralling costs are driving firms to invest primarily in drugs that tackle diseases of 'older Americans'.

As a result, the international market has been flooded with medicines to treat 'American diseases' such as high blood pressure, obesity, heart disease and cancer, while drugs to tackle tuberculosis, malaria and water-borne diseases prevalent in the poorest countries have been neglected.

Presenting his research at the HPA's annual conference tomorrow, Rhodes will show that more and more pharmaceutical companies are moving their headquarters to the US in search of profits. Once there, they pump money into treatments that help the local population to live longer.

'Drugs and vaccines are becoming phenomenally expensive to develop,' said Rhodes. 'Companies have to recoup their investments by selling the drugs and vaccines. To be economic, they need a large population and the price has to be high. That increasingly means that drugs are developed for older Americans, who are getting healthier and living longer.'

Costs are soaring, added Rhodes, because of extensive safety and efficacy testing and the fact that many drugs that show 'early promise' never make it through the checks.

As such, companies looking to be 'economic' shift resources to meet the needs - and benefit from the profits - of the biggest spenders. 'The US tend to get the first bite of the cherry,' admitted Rhodes.

He said the trend had led to a 'vicious' circle in the poorest countries of 'low economic growth leading to poor healthcare systems, creating a higher burden of disease which in turn affects the ability of the population to develop economically'. But while sub-Saharan Africa is heavily affected, China and India's strong investment in their pharmaceutical industry has seen health improvements and economic bonuses that will in turn attract investment back.

Nevertheless, with many private companies turning their back on the developing world, Rhodes said research was heavily dependent on philanthropic funding and government backing.

He welcomed the International Finance Facility for Immunisation - the funding arm of the Global Alliance for Vaccines and Immunisation - that was launched on Friday. The group has pledged to raise $4 billion (£2.2bn) for an immunisation programme in the developing world.



Go to Original Article >>>

The views expressed herein are the writers' own and do not necessarily reflect those of Looking Glass News. Click the disclaimer link below for more information.
Email: editor@lookingglassnews.org.

E-mail this Link   Printer Friendly




Untitled Document
Disclaimer
Donate | Fair Use Notice | Who We Are | Contact
Copyright 2005 Looking Glass News.